Core Insights - Tilray Brands, Inc. (TLRY) is set to report its third-quarter fiscal 2026 results on April 1, 2026, with expected revenues of $205.9 million, reflecting a 10.9% increase year-over-year, and a narrower loss of 14 cents per share compared to a loss of $1 in the same quarter last year [1][9] Group 1: Financial Performance - The Zacks Consensus Estimate indicates a revenue increase to $205.9 million, up 10.9% from the previous year [1][9] - The expected quarterly loss is 14 cents per share, which is an improvement from the $1 loss reported in the year-ago quarter [1][9] - In the last reported quarter, the company experienced a negative earnings surprise of 192.9%, with an average negative surprise of 19.1% over the last four quarters [2] Group 2: Business Strategy and Focus - Tilray Brands is focused on creating a diversified global consumer packaged goods platform, emphasizing cannabis, beverages, and wellness, with a particular focus on higher-margin opportunities in international markets like Europe [3][4] - The company aims to strengthen its position in the medical cannabis sector through research and clinical trials, alongside a broad product portfolio [3][4] - The strategy includes expanding access, fostering innovation, and supporting regulatory progress globally, which is expected to positively impact performance [4] Group 3: Challenges and Market Conditions - Despite the positive outlook, Tilray Brands faces underlying weaknesses, including margin pressures due to a higher mix of lower-margin cannabis products and ongoing challenges in the beverage segment [5][9] - The beverage business is projected to generate revenues of $47.6 million, down 15% from the previous year, reflecting ongoing SKU rationalization and headwinds in the craft beer segment [5][6] - Management is optimistic about the beverage category's potential, focusing on product diversification and operational improvements [6]

Top Canadian Cannabis Stocks to Watch in March 2026The Canadian cannabis sector continues evolving as global opportunities expand. Many companies are now positioning for U.S. entry. Additionally, federal reform discussions in the United States remain a major catalyst. As a result, investors are closely watching key Canadian names. However, volatility remains high, so proper risk management is essential.At the same time, companies are diversifying into beverages, wellness, and international markets. This hel ...

The company introduced Shock Top’s first-ever high-ABV offering, High Voltage, as part of its broader push to expand and innovate within the beverage segment. The product is a double wheat beer with a 9.6% ABV, featuring bold orange flavors and real orange peel.This new product is expected to roll out in stores nationwide starting at $2.99, reflecting the brand’s commitment to meeting consumer demand for high-ABV options.The launch will begin in Southern California before expanding further, showcasing Shock ...

A Double Wheat Brew that Surges with Big, Shocking Citrus, Shock Top High Voltage is Boldly Strong at 9.6% ABV PORTLAND, Ore., March 31, 2026 (GLOBE NEWSWIRE) -- Shock Top, a craft beer icon and brand by Tilray Beverages, known for its bold flavors and unfiltered wheat ales, today announced its first-ever high-ABV double wheat beer, an electric new twist on what a wheat can be. High Voltage delivers a shockwave of juicy orange flavor amped by bright citrus zest and a bold wheat backbone. Prepare to be jolte ...

Core Viewpoint - Tilray Brands, Inc. has partnered with The Magnum Ice Cream Company to launch a new line of ready-to-drink alcoholic beverages inspired by iconic Popsicle flavors, targeting adult consumers in the U.S. market [3][4]. Company Overview - Tilray Brands, Inc. is a leading global lifestyle and consumer packaged goods company, listed on Nasdaq and TSX [3]. - The Magnum Ice Cream Company is the world's largest ice cream company, generating €7.9 billion in revenue in 2025, with a presence in 80 markets [6][7]. Product Launch - The new Popsicle® Hard flavored beverages will feature a 5% ABV and include flavors such as Hard Cherry, Hard Orange, and Hard Grape, available in a variety pack [4]. - The Popsicle Hard Variety Pack will be available in select retailers nationwide starting March 2026, with a special Popsicle Hard Firecracker beverage launching in May 2026 [4][5]. Strategic Goals - The partnership aims to leverage Tilray's beverage innovation expertise and Popsicle's nostalgic brand appeal to create a unique adult refreshment experience [5]. - The initiative reflects Tilray's strategy to build a dynamic portfolio of brands that resonate with consumers across various occasions [5].

Core Viewpoint - Tilray Brands, Inc. is set to release its financial results for the third fiscal quarter ending February 28, 2026, on April 1, 2026, before market opening [1] Group 1: Financial Results Announcement - The financial results will be announced before the financial markets open on April 1, 2026 [1] - A live conference call and audio webcast will be held at 8:30 AM Eastern Time on the same day to discuss the results [2] Group 2: Company Overview - Tilray is a leading global lifestyle and consumer packaged goods company with operations in multiple regions including Canada, the United States, Europe, Australia, and Latin America [3] - The company focuses on the cannabis, beverage, wellness, and entertainment sectors, aiming to elevate lives through moments of connection [3] - Tilray supports over 40 brands in more than 20 countries, offering a range of products including cannabis offerings, hemp-based foods, and craft beverages [3]

Core Insights - Irwin Simon, CEO of Tilray Brands, is expanding the company's beer offerings by acquiring UK-based BrewDog for $53 million, significantly lower than its peak valuation of $2 billion [1][4] - The acquisition is part of Simon's strategy to revitalize declining brands, leveraging his experience from his time at Hain Celestial Group [2] Company Strategy - Tilray was already the fourth-largest craft brewer in the US by sales volume before the BrewDog acquisition [3] - The company plans to market BrewDog's products to millennials and Gen Z through pop-up events at various locations, including East Hampton's Maidstone Hotel and Lobster Roll's Hamptons locations [3][5] - Simon aims to sell Tilray's craft beers, including Montauk Brewing Co. beverages, at BrewDog pubs in both the US and Europe [5][8] Market Positioning - BrewDog, known for its rebellious image, faced challenges due to overexpansion, which included opening multiple locations across several countries [2][9] - Simon is optimistic about the brand's potential in the UK and the US, despite rising anti-US sentiment in Europe [8]

Core Viewpoint - James Watt has expressed disappointment over Tilray Brands' decision to exclude early investors, known as "equity punks," from the recent acquisition of BrewDog, which he founded in 2007 [2][5]. Group 1: Acquisition Details - Tilray Brands acquired BrewDog's brand, brewery, and 11 pubs for £33 million, a significant drop from BrewDog's previous valuation of £1 billion [4][8]. - TSG Consumer Partners, which invested in BrewDog in 2017, did not participate in the sale and left empty-handed, along with James Watt and co-founder Martin Dickie [4]. Group 2: Investor Impact - The acquisition resulted in the complete loss of investments for BrewDog's equity punks, which Watt criticized as unacceptable [5][6]. - Watt had previously positioned himself as a protector of these smaller investors, indicating that he would ensure they retained equity if he had acquired the business [4][5]. Group 3: Management and Future Direction - Irwin Simon, Tilray's CEO, has indicated a desire to move past Watt's involvement and the associated controversies, including claims of a toxic workplace culture [7]. - Simon stated that by the time he took over, there was "no money left," highlighting the financial challenges faced by BrewDog [9].

Core Viewpoint - Tilray is expanding its product offerings in Australia, focusing on enhancing treatment options for healthcare professionals and patients, which reflects its commitment to this key growth market [1][5]. Product Expansion - The expansion includes new products under the Redecan and Good Supply brands, offering medical cannabis flower, extracts, vapes, and pastilles to improve access to high-potency, patient-focused solutions [1][5]. Market Performance - Despite a broader market decline, Tilray's stock movement is more influenced by general market trends rather than company-specific issues, with the Materials sector down 2.18% [2]. - Tilray's stock is currently trading 11.3% below its 20-day simple moving average (SMA) and 30% below its 100-day SMA, indicating a bearish trend in the short- to medium-term [3]. Technical Analysis - The Relative Strength Index (RSI) is at 32.93, indicating neutral territory, while the Moving Average Convergence Divergence (MACD) is at -0.3179, suggesting bearish pressure on the stock [4]. - Key resistance level for the stock is identified at $7.00 [4]. Earnings and Analyst Outlook - The next financial update for Tilray Brands, Inc. is estimated to be on April 7, 2026 [6]. - The stock currently carries a Hold Rating, with Roth Capital recently lowering its target price to $10.00 [7]. ETF Exposure - Tilray has a significant weight of 15.49% in the Amplify Alternative Harvest ETF (NYSE:MJ), indicating that any significant inflows or outflows for this ETF will likely impact Tilray's stock price [8]. Price Action - As of the latest publication, Tilray's stock price was down 2.01% at $6.59, with an estimated loss of 1 cent per share and a revenue estimate of $203.15 million, up from $185.78 million [9].

Core Viewpoint - Tilray's stock price has significantly declined, losing crucial support, raising concerns about a potential drop to $5 as demand for cannabis companies decreases [1][6]. Group 1: Stock Performance - Tilray's stock (TLRY) fell to $6.7, marking its lowest level since August of the previous year, and has dropped 72% from its peak last year [1]. - The stock has decreased from $23.23 to $6.73, reflecting a broader trend in the cannabis sector, with the AdvisorShares Pure US Cannabis ETF (MSOS) also declining from $7.25 to $3.78 [2][6]. Group 2: Market Catalysts - The decline in Tilray's stock is attributed to waning hype surrounding the potential reclassification of cannabis in the U.S., with the Trump administration not addressing the issue since last year [2][3]. - The anticipated reclassification could significantly impact the cannabis industry by allowing easier expansion into the U.S. market, which Tilray currently does not serve [3]. Group 3: Financial Performance - Despite the stock decline, Tilray's net revenue increased by 3% to $217 million in the second quarter, with the cannabis segment also seeing a 3% rise to $67.5 million [4]. - Distribution revenue, including Tilray Pharma, rose to $85.3 million from $67.5 million year-over-year [5]. - The company's gross profit grew from $8.4 million to $11 million, and net losses narrowed from $85.3 million to $43.5 million [7]. Group 4: Future Projections - Analysts predict continued revenue growth for Tilray, estimating an 8.38% increase to $201 million, with annual revenue projected to rise by 5.2% to over $864 million in the current fiscal year, and reaching $1.1 billion next year [8]. Group 5: Technical Analysis - The stock has fallen below the critical support level of $6.97, indicating a potential further decline, with the next target being the $5 support level, representing a 25% drop from the current price [9][10].